Canada Investigational New Drug Cdmo Market Size & Outlook
Related Markets
Canada investigational new drug cdmo market highlights
- The Canada investigational new drug cdmo market generated a revenue of USD 264.4 million in 2021 and is expected to reach USD 429.2 million by 2028.
- The Canada market is expected to grow at a CAGR of 7.2% from 2022 to 2028.
- In terms of segment, small molecule was the largest revenue generating product in 2021.
- Large Molecule is the most lucrative product segment registering the fastest growth during the forecast period.
Investigational new drug cdmo market data book summary
| Market revenue in 2021 | USD 264.4 million |
| Market revenue in 2028 | USD 429.2 million |
| Growth rate | 7.2% (CAGR from 2021 to 2028) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | Labcorp Holdings Inc, Charles River Laboratories International Inc, Cambrex, IQVIA Holdings Inc, Syneos Health, Lonza Group Ltd, Catalent Inc, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 6.2% of the global investigational new drug cdmo market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. investigational new drug cdmo market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 429.2 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Investigational New Drug CDMO Market Scope
Investigational New Drug CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | http://www.cambrex.com |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | https://www.syneoshealth.com/ |
| IQVIA Holdings Inc | View profile | 87000 | 2400 Ellis Road, Durham, NC, United States, 27703 | https://www.iqvia.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Canada investigational new drug cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to investigational new drug cdmo market will help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of 88.8% in 2021. Horizon Databook has segmented the Canada investigational new drug cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2028.
- Canada Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018-2028)
- Large Molecule
- Small Molecule
- Canada Investigational New Drug CDMO Services Outlook (Revenue, USD Million, 2018-2028)
- Contract Development
- Small Molecule
- Bioanalysis and DMPK studies
- Preclinical formulation selection
- Analytical method development / validation
- Work up Purification Steps
- Telescoping & Process Refining
- Formal stability of drug substance and drug product
- Scale-up of drug substance
- Initial Optimization
- Pathology and safety pharmacology studies
- Form selection crystallization process development
- Toxicology Testing
- Drug substance synthetic route development
- Drug substance process development
- Preformulation
- First in Man Formulation/ Process Development
- Release testing of drug substance and drug product
- Large Molecule
- Process Development
- Upstream
- Microbial
- Others
- Mammalian
- Downstream
- MABs
- Others
- Recombinant proteins
- Upstream
- Cell Line development
- Process Development
- Small Molecule
- Contract Manufacturing
- Small Molecule
- Oral Solids
- Injectables
- Others
- Liquid and Semi-solids
- Large Molecule
- Recombinant proteins
- MABs
- Others
- Small Molecule
- Contract Development
- Canada Investigational New Drug CDMO End Use Outlook (Revenue, USD Million, 2018-2028)
- Others
- Biotech Companies
- Pharmaceutical Companies
- Large
- Small
- Medium
Reasons to subscribe to Canada investigational new drug cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada investigational new drug cdmo market databook
-
Our clientele includes a mix of investigational new drug cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada investigational new drug cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Canada investigational new drug cdmo market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Canada investigational new drug cdmo market size, by product, 2018-2028 (US$M)
Canada Investigational New Drug CDMO Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
